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Tumor necrosis factor alpha







RTumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients withdiseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inﬂammatory diseases. In thelast years, there has been a growing interest in the role that inﬂammatory cytokines, which sustain the path-
ogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression
of chronic heart failure.
In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF
alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials.
Patients with rheumatoid arthritis have an increased risk for cardiovascular disease and anti-TNF alpha therapy
seems to be beneﬁcial on the risk of cardiovascular disease. In Crohn's disease the increased risk of cardiovascular
disease is controversial and therefore it is impossible to demonstrate an effect in reduction of the risk; however,
heart failure in patients treated with anti-TNF alpha, despite in a small proportion, has been observed.
On the basis of this observation, anti-TNF alpha therapy is contraindicated in patients with Crohn's disease
and III–IV New York Heart Association heart failure class.





























Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged
as an effective therapy for patients with diseases as Crohn's disease
(CD), rheumatoid arthritis (RA), and other chronic systemic inﬂamma-
tory diseases (CSID) [1]. CSID represent a large group of diseases that
may involve all organs and also the heart [2].
Several biologic agents that inhibit tumor necrosis factor (TNF)
alpha are available for use in the treatment of RA. Etanercept is a re-
combinant fusion protein that consists of the soluble TNF receptor
(p75) linked to the Fc portion of human IgG1 (TNFR:Fc). Inﬂiximab
is a chimeric (human/murine) IgG1 monoclonal antibody directed
against TNF. Adalimumab is a fully humanized IgG1 monoclonal anti-
body that inhibits TNF. Golimumab is a human IgG1 kappa monoclo-
nal antibody speciﬁc for human TNF-alpha that neutralizes TNF-alpha
activity. Certolizumab pegol (CZP) is a human anti-TNF-alpha anti-
body Fab′ fragment that is chemically linked to polyethylene glycol.
It neutralizes membrane-associated and soluble TNF-alpha.
In CD, three anti-TNF- alpha therapies are approved for treatment
of in adults in the United States and all are effective in treatment of
luminal Crohn's disease: inﬂiximab, adalimumab, and certolizumab
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and in the United States.
As a consequence, this variety of approaches could explain the dif-
ference in the clinical response in the different diseases in which they
are used. For example, etanercept has an Fc domain of IgG1 attached
to the active receptor, while only inﬂiximab ﬁxes complement and
causes citotoxicity-mediated destruction of TNF alpha producing
cell. There may be differences in binding afﬁnities that could account
for a potential difference in response rates in CD, but such differences
have not been clinically relevant in patients with RA. It is also possible
that for some as yet unexplained reason, etanercept is not available to
the gut mucosa [3].
In the last years, there has been a growing interest in the role that
inﬂammatory cytokines, which sustain the pathogenesis of CSID, play
in regulating cardiac structure and function, particularly in the pro-
gression of chronic heart failure (CHF) [4].
CHF represents a major public health burden, and its prognosis is
comparable to that of different malignant diseases. It has been
shown that CHF progress because of activation of neuro-hormones
and pro-inﬂammatory cytokines following an initial cardiac injury
or a mutation of the genetic program [5]. Virtually any heart disease
can ultimately lead to heart failure, although the initial event leading
to the development of this syndrome is in many cases unknown [6].
Anyway, the activation of the immune system has received consider-
able interest in its role of maintenance and worsening of CHF, and
several strategies to counterbalance different aspects of the inﬂam-
matory response are considered.deration of Internal Medicine.






































































































































Aim of this review is to analyze the following items:
1. The role of TNF-alpha in CHF
2. The role of anti-TNF-alpha therapies in CHF
3. The risk of cardiovascular diseases in all the CSID (as CD, RA, etc)
requiring anti TNF-alpha therapies
4. The impact of biologic therapies on the cardiovascular diseases
associated with CSID
2. Methods
Medline and the Cochrane Library electronic databases were
searched until July 1, 2012. The keywords included “congestive heart
failure”, “heart failure”, “CHF”, “coronary artery disease”, “atherosclerosis”,
“tumor necrosis factor antagonists”, “biologic therapies”, “inﬂiximab”,
“etanercept”, “adalimumab”, “certolizumab pegol”. No language, date
or age restrictions were applied. Due to the paucity of published clinical
trials evaluating the use of anti-TNF alpha agents in CHF and heart
disease, the review articles summarizing the recent clinical trials were
also reviewed. The reference lists from the published clinical trials and
review articles were examined in order to identify any additional studies.
3. The role of TNF-alpha in CHF
More than two decades ago, Levine and coworkers demonstrated
increased serum levels of TNF-alpha in patients with advanced heart
failure [7]. Subsequently, there has been interest in the role that
TNF alpha plays in regulating cardiac structure and function, particu-
larly in the progression of CHF.
Initially it was not clear whether elevated levels of TNF alpha in CHF
play a direct pathologic role or whether they are merely by-products of
immune stimulation. Subsequent studies have suggested that TNF-
alpha may also have an indirect role on the cardiovascular system [4].
Yokohama and coworkers showed that TNF-alpha exerted a con-
centration and time-dependent inotropic effect, when applied to the
feline ventricle and the isolated feline miocyte, and this effect was
fully reversible after the cytokine removal [8].
Furthermore, a continuous TNF-alpha infusion in rats, at levels
comparable with those reported in patients with CHR, resulted in a
time-dependent depression in left ventricular function, negative
inotropic effect and remodeling, that was partially reversed when
TNF-alpha infusion was stopped [9]. Similar ﬁndings were noted
also in dogs [10].
However, these ﬁndings were obtained in animals with normal
cardiac function and not myocardial injury, prior to TNF-alpha infusion.
TNF-alpha contributes to the progression of CHF through a variety of
mechanisms [11]. In the failing heart, TNF-alpha [1] induces ß-adrener-
gic receptor uncoupling [12,2] increases reacting oxygen species (ROS)
formation [13], and [3] increases inducible Nitric Oxide Sinthases
(iNOS) synthesis resulting in high output NO formation [13]—all con-
tributing to contractile dysfunction. In addition, TNF-alpha increases
the production of other inﬂammatory cytokines (such as IL-6 and
IL-1) which enhance the TNF-alpha-induced myocardial dysfunction
[14,15]. Furthermore, TNF-alpha induces the down-regulation of con-
tractile proteins such as alpha-myosin heavy chain and cardiac alpha-
actin in cardiomyocytes of failing hearts, associated with a further
decrease in contractile function [16].
Apart from its functional effects, sustained expression of TNF-alpha
at high concentrations contributes to structural alterations in the failing
heart, such as cardiomyocyte hypertrophy, increased cardiomyocyte
apoptosis and cardiac ﬁbrosis [17].
In healthy subjects, increased circulating plasma levels of TNF-alpha
predict the risk for cardiovascular diseases [18–20] especially in men
[21]. An increased circulating TNFa concentration correlates to the im-
pairment in cardiac function [22,23] and is an independent predictor
of reduced event-free survival [20], the development of heart failurePlease cite this article as: Sinagra E, et al, Heart failure and anti tumor ne







in asymptomatic patients without prior MI [24,25], andmortality in pa-
tients with advanced heart failure [26–28].
A sustained increase in the myocardial TNF-alpha concentration is
associated with reduced left ventricular function, increased left ven-
tricular dilatation and severe morphological alterations (hypertrophy,
apoptosis and ﬁbrosis). Most of the detrimental effects of TNF-alpha
are TNFR1-dependent. In patients with advanced heart failure, the
circulating TNFα concentration is an independent predictor of mor-
tality [29].
4. The role of anti-TNF-alpha therapies in CHF
Despite the encouraging results of small pilot trials with
etanercept [30,31], the results of large multicenter trials of etanercept
named RENAISSANCE (Randomized Etanercept North AmerIcan
Strategy to Study AntagoNism of CytokinEs), RECOVER (Research into
Etanercept CytOkine antagonism in VEntriculaR dysfunction) and
RENEWAL (Randomized EtaNercEptWorldwide evALuation) inmoder-
ate to severe heart failure did not demonstrate any clinical beneﬁts and
suggested that etanerceptmay adversely affect the course of the disease
[32–34].
The etanercept studies recruited a total of 2048 patients.
RENAISSANCE recruited faster than RECOVER. [32] The end of follow-
up was planned for 6 months after the recruitment of the last patient
in either trial. This resulted in a longer median follow-up time in
RENAISSANCE.Within RENAISSANCE and RECOVER a clinical composite
score was used to assess the clinical effects at 24 weeks (primary
endpoint: alpha 0.04). Overall, the number of patients who were
classiﬁed to have “improved”, remained “unchanged” or “worsened”
was similar for patients on placebo or any dose of etanercept
(RENAISSANCE: p=0.17, RECOVER: p=0.34). In RENEWAL (combined
analysis of medium and high dose etanercept vs. placebo), the primary
endpoint (death or CHF hospitalization, alpha 0.01) was not different
between etanercept and placebo (RR 1.10, 95% CI 0.91 to 1.33,
p=0.33). In RENEWAL, the secondary endpoint (all-cause mortality)
was not different between etanercept and placebo (RR 1.13, 95% CI
0.86 to 1.50, p=0.39). For the endpoint death or CHF hospitalization,
it seems clear that etanercept (compared to placebo) caused more
problems in RENAISSANCE (i.e. in North group America) than in
RECOVER (i.e. in Europe). This is despite the somewhat higher frequen-
cy of infections due to etanercept vs. placebo in the RECOVER trial.
Other data, such as injection site reactions or the total number of hospi-
talizations (for any reason) and of deaths, are not yet available. From the
Kaplan Meier curves the 1-year mortality in the RENEWAL population
(excluding the low dose group in RECOVER), is 15 to 16%, and the sur-
vival curves for placebo and etanercept treated patients overlapped
throughout the ﬁrst year [35]. Given the higher doses of etanercept in
the RENAISSANCE/RECOVER programme than in the previous studies,
it seems important to know the effects on totalmortality for the individ-
ual dose levels. Thesewere not reported. Of particular interestwould be
the total mortality in the 375 patients with 25 mg etanercept once
weekly (from RECOVER) compared to the 373 patients on placebo in
that study. If there were a beneﬁt in the etanercept group, for many
this may change the outlook on these studies and the potential of
anti-TNF therapy in general in CHF. Inﬂiximab has been shown to im-
prove left ventricular functions and to limit heart failure in transgenic
mice associated with overexpression of TNF-a [36]. However, the
ATTACH (Anti TNF-alpha Therapy Against Chronic Heart failure) trial
of inﬂiximab concluded that TNF-alpha antagonism with inﬂiximab
did not improve heart failure, but it adversely affected clinical status
of patients with moderate to severe heart failure [37].
In ATTACH, 150 patients in New York Heart Association (NYHA) III/IV
classes were recruited (in NYHA IV: 0.10%). In the placebo group
(n=549), none of the patients died during 28 weeks of follow-up.
This seems surprising given that this was reported to be a patient
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seems to have had less advanced heart failure than that recruited for
RENAISSANCE or RECOVER (28-week mortality in the placebo group
of RENEWAL: about 6% [38]). The NYHA classiﬁcation is very subjective
and may not adequately reﬂect disease severity, particularly if this is
(besides Left Ventricular Ejection Fraction [LVEF]) the main inclusion
criterion for a study. In an analysis that was extended to 38 weeks, 1
death was observed in the placebo group, 2 patients died in the
5 mg/kg group (4%), whereas 6 of the patients treated with 10 mg/kg
had died (12%) [39]. In RENEWAL, the week mortality in the placebo
group was about 7% [38].
Furthermore, in ATTACH plasma levels of inﬂiximabweremeasured
at regular intervals. It was reported that the therapeutic drug level of
inﬂiximab is 1.0 mg/mL (company representatives have stated that
the therapeutic drug level can be up to 8 mg/mL), however it was also
shown that in this population of elderly CHF patients the achieved plas-
ma levels of inﬂiximabwere between 10 and 100 mg/mL for a period of
at least 19 weeks both in the 5 and 10 mg/kg treatment groups [36]. If
this statement is correct, it appears that ATTACH tested a very high
dose (5 mg/kg) of inﬂiximab and an extremely high dose (10 mg/kg)
of inﬂiximab vs. placebo. The adverse events were restricted to the
group of patients receiving 10 mg/kg inﬂiximab. We cannot know
from ATTACH what the clinical potential of a low or medium doses
of inﬂiximab could be in CHF patients. However, we do know that
5 mg/kg inﬂiximab improved LVEF as assessed at week 14 (p=0.013
vs. placebo) [38].
The data arising from these studies show that inﬂiximab did not
improve but actually worsened CHF, which remained worsened
even after discontinuation of anti-TNF therapy, and that etanercept
should be used with caution in patients with RA and CHF; further-
more these data alerted about the safety of TNF-alpha inhibitors in
patients with chronic CHF. In fact after these trials, every TNF-alpha
antagonist was given an absolute contraindication in patients with
CHF NYHA class III–IV and a relative contraindication in patients
with CHF NYHA class II, as recommended by current guidelines [39].
Intriguingly, several publications signaled the occurrence of der-
matological, intestinal and ophthalmological paradoxical adverse
events, so called because they appears after the initiation of the
anti-TNF alpha drugs, that are normally used to treat them [40].
To date, is not yet clear if heart failure could be considered another
paradoxical adverse event or not. Furthermore, the reasons for which







Features of the main studies investigating the TNF alpha therapies in Chronic Heart Failure
Authors, year Design No.
pati
Deswal, 1999 Randomized double-blind, placebo-controlled, multidose
pilot study of etanercept in Patients with NYHA III heart failure.
18
Bozkurt, 2001 Randomized, double-blind, placebo-controlled, multidose pilot




Large, randomized, phase 2/3 placebo controlled, double-blind




Large, randomized, phase2/3 placebo-controlled, double-blind




A combined analysis of medium and high dose of etanercept. NA
Chung,
2003—ATTACH
Randomized, double-blind, placebo-controlled, pilot trial of
inﬂiximab in patients of NYHA III–IV.
150
Legend:
NYHA—New York Heart Association.
NA—Not Applicable.
RENAISSANCE—Randomized Etanercept North AmerIcan Strategy to Study AntagoNism of C
RECOVER—Research into Etanercept CytOkine Antagonism in VentriculaR dysfunction.
RENEWAL—Randomized EtaNercEpt Worldwide EvALuation.
ATTACH—Anti-TNF-α Therapy Against Chronic Heart Failure.
LV—Left ventricular.
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fully elucidated. First, TNF alpha production could be an epiphenom-
enon or could have an adaptive role in heart failure rather than being
involved in the pathophysiology of the CHF.
Second, TNF blockers could be selectively cytotoxic to failing
myocytes. Inﬂiximab may exert its effects, at least in part, by ﬁxing
complement on cells that express TNF alpha on the membrane.
Finally, Patient selection may have mitigated the efﬁcacy of the
TNF_blockers. Patients in these trials may have been inappropriately
selected. Perhaps the small percentage of patients with the highest
TNF alpha levels would have been the appropriate patients for these
trials [4].
Table 1 shows the designs and the results of the main studies
investigating the anti-TNF-alpha therapies in CHF.
5. The risk of cardiovascular diseases in the chronic systemic
inﬂammatory diseases requiring anti TNF-alpha therapies
5.1. Rheumatoid arthritis
RA is characterized by increased morbidity and mortality for cardio-
vascular disease, which suggests that systemic inﬂammation plays an im-
portant role in raising the risk for atherosclerosis, myocardial infarction,
heart failure and cerebrovascular disease [41–45]. Pro-inﬂammatory cy-
tokines, including TNF-alpha, do not only contribute to the pathogenesis
of RA, but also mediate endothelial dysfunction, vascular instability, and
atherosclerosis progression [7,23,46].
Wolfe and Michaud [47] scrutinized the data from National
Databank for Rheumatic Disease (NDBRD) and found that the preva-
lence of HF, adjusted for demographic differences, was 3.9% in pa-
tients with rheumatoid arthritis in therapy with synthetic disease
modifying anti rheumatic drugs (DMARDs), but was 2.8% in patients
with rheumatoid arthritis in combination therapy with anti-TNF-
alpha agents, with similar incidence (about 0.2%) in both groups.
In 2008, Listing and coworkers [48] used data from the German Bio-
logics Register, the Rheumatoid Arthritis Observation of Biologic Thera-
py (RABBIT), to explore the risk factors for developing HF in RA
population. Age, another cardiovascular disease, body mass index,
DAS 28 and COX-2 inhibitors therapy proved to be signiﬁcant risk
factors for developing de novoHF in patientswith rheumatoid arthritis;
treatment with TNF-alpha inhibitors compared to treatment with
synthetic DMARDs did not reach statistical signiﬁcance. In the same.
of
ents
Follow up Results obtained
14 days Etanercept waswell tolerated and higher doses were associated
with signiﬁcant improvements in quality of life scores,
3 months Treatment with etanercept was safe andwell tolerated in patients
with advanced heart failure and it resulted in a signiﬁcant dose-
dependent improvement in LV structure and function
12.7 months Trial resulted a dose-dependent trend toward increased
all-cause mortality and hospitalizations in etanercept groups
3 5.7 months Terminated and halted in 5.7 months due to poor clinical
outcome like RENAISSANCE
NA A trend toward increased mortality and chronic heart failure
hospitalizations in etanercept-treated group
28 weeks TNF-a antagonism with inﬂiximab did not improve and high
doses adversely affected the clinical condition of patients with
moderate to severe chronic heart failure
ytokinEs.













































































































study, signiﬁcant risk factors for worsening of a pre-existing HF were
male sex and glucocorticoid therapy at a dose level higher than
10 mg/day; again, treatment with TNF-alpha inhibitors did not
prove to be a risk factor for worsening of a pre-existent heart failure
compared to synthetic DMARDs therapy.
In 2005, Jacobsson and coworkers [49] investigated the risk of car-
diovascular disease in RA patients treated with TNF-alpha antagonists
compared to DMARDs treated patients, using patients from a Swedish
Register. They noticed that the risk of developing cardiovascular dis-
ease was lower in RA patients treated with TNF-alpha inhibitors,
which was consistent with the hypothesis that inﬂammation contrib-
utes to the development of cardiovascular events. In 2007, Dixon and
coworkers [50] used data from the British Society for Rheumatology
Biologics Register (BSRBR) and deepened this issue further: they
showed that RA patients treated with anti-TNF-alpha did not have a
lower incidence of myocardial infarction compared with RA patients
treated with traditional DMARDs; however, 6 months therapy with
anti-TNF-alpha markedly reduced the risk of myocardial infarction
in patients with disease improvement compared to non-responders.
The above mentioned ATTACH and RENEWAL trials highlighted
the detrimental effect of TNF-alpha inhibitors in patients with severe
HF, but data from National Registers of RA patients showed that
TNF-alpha inhibitors did not increase but actually reduced the risk
of developing HF. This suggests that the role of TNF-alpha antagonism
in HF may be more complex than previously believed, and uncovered
a “rheumatological” dilemma [51].
Available data support the conclusion that patients with severe
RA, particularly with a high disease activity, have an increased risk
for developing HF. The risk is further increased by treatment with
COX-2 inhibitors and glucocorticoids. Because TNF-alpha inhibitors
are highly effective in suppressing inﬂammatory activity in rheuma-
tological disorders, it is very plausible that these drugs provide a ben-
eﬁcial contribution regarding the risk of cardiovascular disease, and
an effective treatment of both rheumatological and cardiovascular
disease is required for proper management of RA patients. Although
National Registries provide apparently encouraging data about HF
safety of anti-TNF-alpha therapies, they cannot adequately assess
the actual risk, as these drugs are administered to patients with no
cardiac dysfunction.
Table 2 shows the studies investigating the risk of cardiovascular
disease in RA.
5.2. Crohn's disease
With regards to CD, a possible relationship between IBD and cardi-





Studies investigating the risk of cardiovascular disease in patients with rheumatoid arthriti




Wolfe and Michaud [47] INF, ETN vs. DMARD 13,171 15 NR
Jacobsson et al. [49] INF, ETN vs. DMARD 983 11 4 years
Dixon et al. [50] INF, ETN, ADA vs. DMARD 10,755 12 1.7 years





DMARDS: Disease Modifying Anti-Rheumatic Drugs.
RA: Rheumatoid Arthritis.
HF: Heart Failure.
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noted a signiﬁcant increase in ischemic heart disease in both men and
women with IBD compared with age- and sex-matched controls
[52,53]. A subsequent meta-analysis found no association between
IBD and cardiovascular disease mortality. However, with advance-
ments in interventional therapies for cardiac disease, cardiovascular
mortality may not be an appropriate surrogate for incidence [54].
Studies in IBD attempting to show increased carotid intimal–medial
thickness as a measure of atherosclerotic disease burden have shown
conﬂicting results [55,56].
In the study performed byHa and coworkers, it was showed that IBD
patients do, indeed, have an elevated risk for myocardial infarction, but
the risk is limited to women in the 40–59 years age group [54].
There appears to be, in fact, a gender disparity with regard to some
arterial thromboembolic events in IBD. It was observed higher rates of
acute myocardial infarction in older women with IBD, whereas in men
over the age of 40 years, there was no increased risk in myocardial in-
farction and a signiﬁcantly lower risk of atherosclerosiswhen compared
with controls. Moreover, there was a higher rate of cerebrovascular ac-
cidents in younger women, but in men this risk did not reach statistical
signiﬁcance. In general, the cause for a thrombotic tendency in IBD ap-
pears to be secondary to a potent prothrombotic stimulus from local
and systemic inﬂammation, and may be related to disease extent and
severity [57]. Active intestinal inﬂammation may activate the coagula-
tion cascade and upregulate prothrombotic mediators such as Factors
V, VII, and VIII, prothrombin, Fibrinogen, and thromboplastin [58].
Furthermore, an upregulation of pro-inﬂammatory cytokines such as
tumor necrosis factor and interleukin-6 can lead to increased tissue fac-
tor induction, thereby promoting a systemic pro-coagulant state [59].
Numerous studies have shown that thrombosis in IBD is, in most in-
stances, not related to an underlying genetic or acquired thrombophilia
such as Factor V Leiden, homocysteine, prothrombin genemutations, or
antithrombin III deﬁciency [60–64].
Physiological changes in the intestinal vasculature during active
and chronic intestinal inﬂammation may also contribute to the risk
of thromboembolic events. Angiographic studies of IBD patients
reveal increased intestinal microvascular stenosis, abnormal vasa
recta, and diminished blood ﬂow to the intestine. Chronic inﬂamma-
tion within the microvasculature has been shown to result in in-
creased leukocyte adhesion and recruitment, thereby propagating
the inﬂammatory process [65,66]. Collins and co-workers [67] found
that both UC and CD patients exhibit increased platelet aggregation
in the mesenteric vasculature compared with non-IBD controls. Thus,
the intestinal vasculature may be more susceptible to acute arterial
events not only because of increased systemic pro-coagulative factors
but also because of a localized process that may lead to thrombosis,
ischemia, and infarction.s.
Results
Similar incidence (0.2%) of HF in patients treated with DMARDS and with DMARDS
and anti-TNF-alpha therapies
The risk of developing cardiovascular disease was lower in RA patients treated with
TNF-alpha inhibitors
RA patients treated with anti-TNF-alpha did not have a lower incidence of
myocardial infarction compared with RA patients treated with traditional DMARDs
Treatment with TNF-alpha inhibitors did not prove to be a risk factor for worsening
of a pre-existent heart failure compared to synthetic DMARDs therapy.























































































5E. Sinagra et al. / European Journal of Internal Medicine xxx (2013) xxx–xxxIn addition, atherosclerosis and IBD share pathogenetic pathways:
inﬂammatory and immune cells are important constituents of ather-
oma, and atherosclerotic lesions contain factors capable of triggering
an inﬂammatory response [68,69]. C-reactive protein, which is often
elevated during ﬂares of IBD, has been associated with an increased
10-year risk of coronary heart disease regardless of the presence of
conventional cardiac risk factors [70]. The pro-inﬂammatory cytokine
interleukin-6, which is upregulated in IBD and plays an important
role in intestinal inﬂammation [71], was also found to independently
predict the occurrence of vascular events in otherwise healthy
post-menopausal women [72]. It is plausible that the systemic in-
ﬂammatory state associated with IBD may potentiate concurrent
traditional cardiac risk factors in peri- and postmenopausal women,
an effect that has been observed in other chronic inﬂammatory condi-
tions such as rheumatoid and psoriatic arthritis.
In short, IBD patients are at greater risk of venous thromboembolic
events. Patients with IBD have a markedly higher risk of acute mesen-
teric ischemia. Atheroma development in the arterial vasculature may
further predispose women with IBD to future acute myocardial in-
farction and other serious arterial events. Venous thromboembolic
events in IBD are associated with high morbidity, with mortality
rates between 8 and 25% [73]. Given the additional risk for arterial
thromboses, IBD practitioners should be aware of the importance of
recognizing these events and focusing on prevention strategies,
such as smoking cessation and maintaining long-term remission in
IBD.

























6. The impact of biologic therapies on the cardiovascular diseases
associated with systemic inﬂammatory chronic disease
Spontaneous reporting systems such as the FDA Medwatch pro-
gram and other postmarketing surveillance studies are helpful in
suggesting possible safety signals of rare but serious adverse events
after introduction of new agents into the market. These approaches,
however, often have the limitations of underreporting, duplicate
reporting, lack of denominators to determine event rates and diag-
nostic misclassiﬁcation. A series of 38 incident cases of heart failure
and nine heart failure exacerbations in patients (38 had RA) receiving
etanercept or inﬂiximab reported to the FDAMedWatch programwas
published in 2003 [74]. Interestingly, in this study, half of the patients
that experienced new onset heart failure had no identiﬁable tradi-
tional risk factor for heart failure (previous myocardial infarction,
coronary artery disease, hypertension or diabetes mellitus), 10 were




Studies investigating the risk of cardiovascular diseases in Crohn's Disease.
Author, year Design of the study No. of patients Follow
Talbot, 1986 Retrospective study 7199 11 ye
Novotny, 1992 Case report 3 NA
Brown, 2005 Case report 1 NA
Nuutinen, 1995 Retrospective (abstract) NA NA
Nuutinen, 1996 Retrospective (abstract) NA NA
Dorn, 2007 Meta-analysis of 11 studies 4532 patients with CD and
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alpha dose to diagnosis of incident heart failure was 3.5 months
(range of 1 day to 2 years) [74].
Analysis of more than 1600 RA patients treated in controlled clin-
ical trials indicated that new onset CHF occurred in 0.2% of inﬂiximab
and 2.1% of placebo-treated RA and Crohn's disease patients [75].
In recent safety analyses of adalimumab use in patients with RA
[76], 0.3% had new onset heart failure, 7% had worsening heart failure.
This led to an overall rate of heart failure of 0.28 events per 100
patient-years in all RCTs and subsequent open-label extensions com-
pared with a much lower rate of 0.06 events per 100 patient-years in
the postmarketing surveillance [76]. In a nationwide comprehensive
monitoring system for RA patients in Sweden treated with etanercept,
the reported rate of heart failure (reported as serious events) was
0.04 per 100 patient-years [77]. The difference between these rates
may be explained by different methods of reporting and variable
strategies to calculate the patient-year exposure to anti-TNF-alpha
therapy.
Observational studies provide a valuable study design for addressing
the epidemiology of adverse events in a ‘realworld’ context, but they
need to be carefully conducted to have adequate internal validity and
generalizability. Beyond the major challenge of addressing channeling
bias in these studies (confounding by indication), another limitation is
the recurring theme of misclassiﬁcation of heart failure cases. Recent
studies attempted to overcome this major limitation of imprecise
heart failure diagnosis.
In a study of the National Databank for Rheumatic Diseases, heart
failure was reported by a patient and was considered valid if
supported by medical records, physician contact or documentation
that it was diagnosed by a physician [47]. The validity of heart failure
cases was reported to be greater than 90%. Inﬂiximab and etanercept
users had signiﬁcantly less heart failure (3.1%) than non anti-TNF-
alpha users (3.8%), even after adjusting for important covariates
using propensity scores [45]. In this cohort, the rate of incident
heart failure in patients with RA without a history of cardiovascular
disease was 0.4% and was not related to anti TNF-alpha therapy, al-
though the number of cases was small. In patients younger than
50 years of age, no incident cases of heart failure were noted in the
anti-TNF-a group. A limitation of the study is that patients who
were started on anti-TNF-a therapy were less likely to have known
heart failure, although adjusting for the history of heart failure did
not alter the results [47].
A small case–control study of Veteran's Affairs patients with RA
(n=103) evaluated the rate of new and worsening heart failure
after receiving at least one dose of etanercept, inﬂiximab and/or
adalimumab [78]. A RA control group from rheumatology clinic
(n=100) who did not receive TNF-alpha antagonists and a non-RA
control group from a VA primary care clinic (n=100) were used forup Results
ars Thromboembolic complications developed in 92 (1.3%) of the patients;
7 out 92 were arterial ones
Three patients with active pancolonic ulcerative colitis developed arterial
thromboembolic complications prior to surgical treatment
Acute superior mesenteric artery occlusion during active ulcerative colitis
The prevalence of coronary heart disease in the older age group of patients
with UC (>60 years) was signiﬁcantly higher both in males and females
The prevalence of coronary heart disease in the older age group of patients
with CD (>60 years) was signiﬁcantly higher both in males and females
IBD is not associated with increased CV mortality











































































































































comparisons. Heart failure was determined using the ICD-9 code for
systolic heart failure coupled with medical record review. History of
heart failure was present in 13% patients in all the groups. There
were no signiﬁcant differences between the groups with regards to
hospital admissions for heart failure or all-cause mortality. Only one
out of seven patients in the anti-TNF-alpha group had incident heart
failure. The study was limited by the small sample size, a large
range in the follow-up durations between the three anti-TNF-alpha
agents, and a sensitivity of the ICD-9 codes which may be inadequate
for case ﬁnding. Confounding by selection of younger patients with
fewer comorbidities is also a potential concern.
The risk of hospitalization for heart failure associated with the use
of DMARDs in RA was evaluated using administrative claims data
within a cohort of 41 885 patients with RA who were dispensed a
DMARD between September 1998 and December 2001 [79]. The au-
thors discussed the very high positive predictive value of the single
ICD-9 code for heart failure from previous work in Canada, which
may not be generalizable. Over approximately 1 year mean follow-
up, the incidence of heart failure was 1.0 event per 100 person-years.
In this nested case–control study, inﬂiximab and etanercept were
shown to be associated with a lower risk for developing heart failure
with a RR of 0.5 (95% CI: 0.2–0.9) relative to non-DMARD therapy,
after adjustment for a variety of potentially confounding factors
including use of nonsteroidal anti-inﬂammatory drugs and glucocor-
ticoids [79].
The protective effect was consistent with any DMARD groups, par-
ticularly methotrexate monotherapy (RR 0.8, 95% CI: 0.6–1.0). This
result suggests that the beneﬁt was related to the control of inﬂam-
mation by any disease modifying agent and was not unique to
anti-TNF-a agents alone. Potential confounding due to channeling
bias was partially addressed by excluding patients with a history of
heart failure. There was no increase risk of cardiovascular events
even after discontinuation of DMARDs, stopping of drugs just before
the event due to deteriorating health or patients becoming at risk,
could potentially confer a false protective effect of the drugs.
Another recently published study [80] evaluated the risk of inci-
dent heart failure among younger adults with RA and Crohn's disease
(b50 years old) exposed to etanercept or inﬂiximab compared with
those who received nonbiologic immunosuppressives. Heart failure
was initially identiﬁed by diagnosis codes for heart failure on any
claims within 9 months of most recent exposure to a study drug. Sub-
jects with heart failure prior to index date were excluded. Medical re-
cords were then reviewed for elements of the modiﬁed Framingham
criteria for heart failure and ejection fraction. Among 2121 patients
with RA and 1897 with Crohn's disease followed for a mean duration
of 18 months, heart failure was conﬁrmed in nine cases (0.2%). The
relative risk of heart failure trended towards an increased risk at 4.3
for patients with RA who were treated with TNF-alpha antagonist
and 1.2 for those with Crohn's disease, although neither estimate
was statistically signiﬁcant [80]. Had the risk estimate been signiﬁ-
cant, the resultant numbers needed to harm would have been 294
and 3333 for RA and Crohn's disease, respectively. The selection of a
younger population allowed for evaluation of incidence of new
onset heart failure in those with a low prevalence of cardiovascular
comorbidities. Despite being a large cohort of patients with reason-
able follow-up, the small number of events limited the power of
the study and the ability to control for potential confounding by
indication.
A recent study evaluated the mortality from Spanish nationwide
cohorts with RA treated with TNF-alpha antagonists from Spanish So-
ciety of Rheumatology Database on Biologic Products (BIOBADASER)
and those not treated with TNF-α antagonist from the Morbidity
and Clinical Expression of Rheumatoid Arthritis (EMECAR) registry
[81]. Causes of death were obtained from charts, patients' families and
death registries. The patients had similar cardiovascular risk proﬁle,
but the EMECAR patients were older with lower disease activity andPlease cite this article as: Sinagra E, et al, Heart failure and anti tumor ne







more prevalent smoking history. The age-stratiﬁed incidence rates
of heart failure were signiﬁcantly lower in the BIOBADASER cohort
[0.4 (95% CI: 0.2–0.9)/100 person-years] compared with EMECAR
cohort [1.9 (95% CI: 1.3–2.7)/100 person-years]. The mortality rate
ratios (BIOBADASER/EMECAR) due to all-causes and cardiovascular
diseases were decreased at 0.3 (95%CI: 0.02–0.5) and 0.6 (95% CI:
0.2–1.4), respectively, although there was signiﬁcant increase in
rate of infection. There was adjustment for the systematic differ-
ences expected between the two cohorts using propensity scores
[81].
Curiously, a systematic review and meta-analysis including 16 and
11 publications, respectively, [82] showed that in cohort studies,
anti-TNF alpha therapy was associated with a reduced risk for all car-
diovascular events (pooled adjusted RR 0.46; 95% CI 0.28, 0.77), MI
(pooled adjusted RR 0.81; 95% CI 0.68, 0.96), and CVA (pooled adjust-
ed RR 0.69; 95% CI 0.53, 0.89). Meta-analysis of RCTs also produced a
point estimate indicating lower risk of cardiovascular events, but this
was not statistically signiﬁcant (pooled RR 0.85; 95% CI 0.28, 2.59).
Anti-TNF alpha therapy is associated with a reduced risk of all car-
diovascular events, MI, and CVA in observational cohorts. There was
heterogeneity among cohort studies and possible publication bias.
The point estimate of the effect from RCTs is underpowered with
wide 95% CIs, and cardiovascular events were secondary outcomes,
but RCTs also demonstrated a trend toward decreased risk.
In summary, albeit widely variable and imperfect deﬁnitions of
heart failure, clinical studies have not shown an increased risk of
new onset or worsening of clinical heart failure associated with
anti-TNF-a therapies in patients with RA. The incidence of CHF in pa-
tients with CSID using anti TNF alpha therapy is low and probably not
underestimated; the ﬁrst reports of CHF in these subsets of patients
were made in patients not screened for cardiovascular disease when
undergoing anti-TNF therapies, thus allowing successively to gain
the awareness for the need of a close surveillance, to avoid using
this therapy when cardiovascular disease is suspected.
7. Conclusions
In conclusion, data regarding the risk of CHF with the use of
anti-TNF-alpha inhibitors at the FDA approved dose are inconclusive.
However, the labels of etanercept, inﬂiximab, and adalimumab
contain the following disease-related concern: “Use with caution in
patients with HF or decreased left ventricular function; worsening
and new-onset HF has been reported.” In addition, inﬂiximab is
contraindicated at doses higher than 5 mg/kg in patients with moder-
ate or severe HF (NYHA class III/IV). The golimumab and certolizumab
pegol labels include similar wording.
Given the evidence to date, in patients with symptomatic HF, we
suggest that treatment strategies other than TNF-alpha inhibitors
should be employed. In a patient who develops HF while on a
TNF-alpha inhibitor, a drug-induced cause should be suspected, and
use of the medication should be suspended.
For patients with RA and mild (NYHA functional class I or II) CHF
whose arthritis is refractory to other DMARDs or biologic agents
(i.e. tocilizumab, rituximab, abatacept), targeted TNF-alpha inhibition
might be considered. In CD, the alternative treatment may be another
biologic drug which is not an anti-TNF alpha (i.e. ustekinumab,
natalizumab). In ulcerative colitis, cyclosporine is a valid alternative
to anti TNF alpha or, alternatively and if necessary, surgery could be
considerate.
If the use of anti-TNF-alpha treatment is entertained, we suggest to
consider a cardiology consultation with baseline echocardiography,
maintaining a close follow-up. Furthermore, it should be advisable the
avoidance of high TNF-alpha inhibitor doses (e.g., more than inﬂiximab
3 mg/kg, adalimumab 40 mg every two weeks, or etanercept
50 mg/week) and the prompt discontinuation of anti-TNF-alpha thera-






































































































































































• What is already known?
The role that inﬂammatory cytokines, which sustain the pathogene-
sis of CSID, play in regulating cardiac structure and function, particularly
in the progression of chronic heart failure
• What should we learn?
– data regarding the risk of CHF with the use of anti-TNF-alpha
inhibitors at the FDA approved dose are inconclusive
– in patients with symptomatic HF, we suggest that treatment strate-
gies other than TNF-alpha inhibitors should be employed
– in a patientwho develops HFwhile on a TNF-alpha inhibitor, a drug-
induced cause should be suspected, and use of the medication
should be suspended.
– if the use of anti-TNF-alpha treatment is entertained, we suggest
to consider a cardiology consultation with baseline echocardiog-
raphy, maintaining a close follow-up
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